Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Rhea-AI Summary

Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company, announced its participation in the Canaccord Genuity 42nd Annual Growth Conference in Boston from August 8-11, 2022. CEO Brian Sullivan will present on August 10 at 11:30 a.m. ET. A live webcast will be accessible via this link and from the company's Investors section. Celcuity focuses on developing targeted therapies for hormonally driven cancers, including its lead candidate gedatolisib, expected to enter Phase 3 trials for advanced breast cancer in 2022.

News Market Reaction – CELC

+10.74%

+10.74% Session move

In the trading session that priced this news, CELC gained 10.74%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, MN / ACCESSWIRE / August 3, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced its participation in the Canaccord Genuity 42nd Annual Growth Conference to be held in Boston on August 8-11, 2022. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, is scheduled to present at 11:30 a.m. ET on Wednesday, August 10, 2022.

A live webcast of the presentation will be available using this weblink: https://wsw.com/webcast/canaccord76/celc/2413629. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live event.

About Celcuity

Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers. The company's lead therapeutic candidate is gedatolisib, a potent, reversible dual inhibitor that selectively targets all Class I PI3K isoforms and mTOR. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. The company expects to initiate a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.

Contacts:

Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123

ICR Westwicke
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886

SOURCE: Celcuity Inc.

View source version on accesswire.com:
https://www.accesswire.com/710690/Celcuity-to-Participate-in-the-Canaccord-Genuity-42nd-Annual-Growth-Conference

FAQ

What event is Celcuity participating in August 2022?

Celcuity is participating in the Canaccord Genuity 42nd Annual Growth Conference from August 8-11, 2022.

When will Celcuity's CEO present at the conference?

Brian Sullivan, Celcuity's CEO, is scheduled to present on August 10, 2022, at 11:30 a.m. ET.

How can I watch Celcuity's presentation at the conference?

You can watch the presentation live through this webcast link or on the company's Investors section.

What is Celcuity's focus area in biotechnology?

Celcuity focuses on developing targeted therapies for hormonally driven cancers.

What is the lead therapeutic candidate of Celcuity?

Celcuity's lead therapeutic candidate is gedatolisib, a dual inhibitor targeting Class I PI3K isoforms and mTOR.

When does Celcuity expect to begin its Phase 3 study for gedatolisib?

Celcuity expects to initiate a Phase 3 study for gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022.